Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study

Subsai Kongsaengdao, Narong Maneeton, Benchalak Maneeton, Subsai Kongsaengdao, Narong Maneeton, Benchalak Maneeton

Abstract

Background: The short-term quality of life (QoL) in cervical dystonia (CD) after treating with abobotulinum toxin A (Abo-BTX A) and neubotulinum toxin A (Neu-BTX A) have been studied in Thai CD patients. However; the long-term study has not been published.

Objective: The aim of the present study was to determine long-term improvement of the health-related quality of life (HRQoL) after eight injections of Abo-BTX A over 2 years in CD patients.

Patients and methods: A 2-year prospective study on the QoL of CD patients, as measured by HRQoL, before and after receiving eight injections of Abo-BTX A at 3-month intervals over a 2-year treatment period was performed. The disease-specific HRQoL was assessed before and after the treatment by using the Cervical Dystonia Impact Profile-58 (CDIP-58) questionnaire. The general HRQoL was assessed by using the Medical Outcomes 36-Item Short Form Health Survey (SF-36), while depressive disorder screening was assessed by using the Center of Epidemiologic Studies-Depression (CES-D) questionnaire. The SF-36 and CES-D questionnaire were administered before treatment and every 3 months before the next injection for a 2-year period.

Results: A total of 20 CD patients were enrolled from January 2013 to December 2015. CDIP-58 showed a significant improvement after long-term injections of Abo-BTX A in all domains (P < 0.001). However, only vitality domain of SF-36, which assessed general HRQoL, showed a significant improvement after long-term injections (P = 0.037). There was no prevalence of depressive disorder in all patients (CES-D score <20) in this study.

Conclusion: The Abo-BTX A injections at 3-month intervals over a 2-year period improved the CDIP-58 scores, which assess disease-specific HRQoL, as well as an increased vitality domain of general HRQoL. No patient suffered from depression in this study.

Keywords: 36-Item Short Form Health Survey; Cervical Dystonia Impact Profile-58 questionnaire; abobotulinum toxin A; cervical dystonia; depressive disorder; health-related quality of life.

Conflict of interest statement

Disclosure BM has received honoraria and/or travel reimbursement from Lundbeck, Pfizer, and Servier. NM has received travel reimbursement from Lundbeck and Pfizer. SK reports no conflicts of interest in this work. Narong Maneeton and Benchalak Maneeton are husband and wife. Benchalak Maneeton is Subsai Kongsaengdao’s sister.

Figures

Figure 1
Figure 1
Schematic diagram showing progression of 20 subjects from baseline screening. Abbreviations: Abo-BTX A, abobotulinum toxin A; CDIP-58, Cervical Dystonia Impact Profile-58; SF-36, 36-Item Short Form Health Survey; CES-D, Center for Epidemiologic Studies-Depression.
Figure 2
Figure 2
Mean CES-D score assessment at 3-month intervals. Abbreviation: CES-D, Center for Epidemiologic Studies-Depression.

References

    1. Kongsaengdao S, Maneeton B, Maneeton N. Quality of life in cervical dystonia after treatment with botulinum toxin A: a 24-week prospective study. Neuropsychiat Dis Treat. 2017;13:127–132.
    1. Jagota P, Kaewwilai L, Boonrod N, et al. Impact of neu-botulinum-toxinA on the severity and quality of life of cervical dystonia patients. Tremor Other Hyperkinet Move. 2016;6:407.
    1. Jankovic J. Treatment of dystonia. Lancet Neurol. 2006;5(10):864–872.
    1. Comella CL, Thompson PD. Treatment of cervical dystonia with botulinum toxins. Eur J Neurol. 2006;13(Suppl 1):16–20.
    1. Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord. 1991;6(2):119–126.
    1. de Carvalho Aguiar PM, Ozelius LJ. Classification and genetics of dystonia. Lancet Neurol. 2002;1(5):316–325.
    1. Bressman SB, Greene PE. Dystonia. Curr Treat Options Neurol. 2000;2(3):275–285.
    1. Epidemiological Study of Dystonia in Europe Collaborative Group A prevalence study of primary dystonia in eight European countries. J Neurol. 2000;247(10):787–792.
    1. Slawek J, Friedman A, Potulska A, et al. Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections. Funct Neurol. 2007;22(2):95–100.
    1. Costa J, Espirito-Santo C, Borges A, Ferreira JJ, Coelho M, Sampaio C. Botulinum toxin type A versus anticholinergics for cervical dystonia. Cochrane Database Syst Rev. 2005;1:CD004312.
    1. Walker FO. Botulinum toxin therapy for cervical dystonia. Phys Med Rehabili Clin N Am. 2003;14(4):749–766. vi.
    1. Simpson DM, Blitzer A, Brashear A, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1699–1706.
    1. Ferreira JJ, Costa J, Coelho M, Sampaio C. The management of cervical dystonia. Expert Opin Pharmacother. 2007;8(2):129–140.
    1. Brashear A. The botulinum toxins in the treatment of cervical dystonia. Sem Neurol. 2001;21(1):85–90.
    1. Cano SJ, Hobart JC, Edwards M, et al. CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia. Neurology. 2006;67(12):2230–2232.
    1. Brans JW, Lindeboom R, Aramideh M, Speelman JD. Long-term effect of botulinum toxin on impairment and functional health in cervical dystonia. Neurology. 1998;50(5):1461–1463.
    1. Pekmezovic T, Svetel M, Ivanovic N, et al. Quality of life in patients with focal dystonia. Clin Neurol Neurosurg. 2009;111(2):161–164.
    1. Hakkinen A, Ylinen J, Rinta-Keturi M, Talvitie U, Kautiainen H, Rissanen A. Decreased neck muscle strength is highly associated with pain in cervical dystonia patients treated with botulinum toxin injections. Arch Phy Med Rehab. 2004;85(10):1684–1688.
    1. Hilker R, Schischniaschvili M, Ghaemi M, Jacobs A, Rudolf J. Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia. J Neurol Neurosurg Psychiatry. 2001;71(2):193–199.
    1. Wenzel T, Schnider P, Wimmer A, Steinhoff N, Moraru E, Auff E. Psychiatric comorbidity in patients with spasmodic torticollis. J Psychosom Res. 1998;44(6):687–690.
    1. Albanese A, Asmus F, Bhatia KP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol. 2011;18(1):5–18.
    1. Albanese A, Barnes MP, Bhatia KP, et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol. 2006;13(5):433–444.
    1. Poungvarin N, Viriyavejakul A. Botulinum A toxin treatment in spasmodic torticollis: report of 56 patients. J Med Assoc Thai. 1994;77(9):464–470.
    1. Bhidayasiri R. Treatment of complex cervical dystonia with botulinum toxin: involvement of deep-cervical muscles may contribute to suboptimal responses. Parkinsonism Relat Disord. 2011;17(Suppl 1):S20–S24.
    1. Hefter H, Benecke R, Erbguth F, Jost W, Reichel G, Wissel J. An open-label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin A (Dysport) BMJ Open. 2013;3(4):e001853.
    1. Skogseid IM, Malt UF, Roislien J, Kerty E. Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia. Eur J Nurol. 2007;14(10):1129–1137.
    1. Mordin M, Masaquel C, Abbott C, Copley-Merriman C. Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinum toxin A (Dysport): results from a randomised, double-blind, placebo-controlled study. BMJ Open. 2014;4(10):e005150.
    1. Radloff LS. A self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401.
    1. Blank K, Gruman C, Robison JT. Case-finding for depression in elderly people: balancing ease of administration with validity in varied treatment settings. J Gerontol A Biol Sci Med Sci. 2004;59(4):378–384.
    1. Trangkasombat U, Likanapichitkul D. The Children’s Depression Inventory as a screen for depression in Thai children. J Med Assoc Thai. 1997;80(8):491–499.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅